| abstract |
An anti-FcyRIIB antibody is provided. The antibody significantly increases ITIM phosphorylation of FcyRIIB in comparison with a conventional antibody, and can be used for treating or preventing an autoimmune disease. The antibody comprises (i) an H-CDR1 sequence that is at least 60% identical to the H-CDR1 sequence, (ii) an H-CDR2 sequence that is at least 36% identical to the H-CDR2 sequence, and (iii) an H-CDR3 sequence. H-CDR3 sequence that is 50% or more identical to L-CDR1 sequence, (iv) L-CDR1 sequence that is 64% or more identical to L-CDR1 sequence, (v) L-CDR3 sequence that is 29% or more identical to L-CDR2 sequence A CDR2 sequence, and (vi) an L-CDR3 sequence that is 78% or more identical to the L-CDR3 sequence. [Selection diagram] None |